Several agents directed against the VEGF/VEGF receptor (VEGFR) signaling pathway have been developed and are now approved across several indications, although the first targeted antiangiogenic drug authorized for use in cancer patients was bevacizumab, a humanized monoclonal antibody that targets VEGF-A to prevent its interaction with VEGFR-1 and -2 [107]. The gene discussed is VEGFA; the disease is cancer.